title: Biliary tract cancers: SEOM clinical guidelines.
abstract: Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. Multidetector-row computed tomography (MDCT) and magnetic resonance cholangio-pancreatography (MRCP) are the more important diagnostic techniques. Surgery is the only potentially curative therapy but disease recurrence is frequent. Treatment with chemotherapy, radiotherapy or both has not demonstrated survival benefit in the adjuvant setting. Cisplatin plus gemcitabine constitutes the gold standard in metastatic disease. New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease.
authors.affiliation: Hospital Universitario Regional y Virgen de la Victoria, Málaga, Spain. manuel.benavides.sspa@juntadeandalucia.es.
authors.forename: M
authors.initials: M
authors.lastname: Benavides
authors.affiliation: Hospital Universitario Miguel Servet, Zaragoza, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Antón
authors.affiliation: Hospital General Universitario, Elche, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Gallego
authors.affiliation: Hospital Universitario Reina Sofía, Córdoba, Spain.
authors.forename: M A
authors.initials: MA
authors.lastname: Gómez
authors.affiliation: Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Jiménez-Gordo
authors.affiliation: Hospital Universitario Donostia, San Sebastián, Spain.
authors.forename: A
authors.initials: A
authors.lastname: La Casta
authors.affiliation: Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Laquente
authors.affiliation: Hospital Universitario Vall d'Hebron e Instituto de Oncología Vall d'Hebron, Barcelona, Spain.
authors.forename: T
authors.initials: T
authors.lastname: Macarulla
authors.affiliation: Hospital Infanta Cristina, Badajoz, Spain.
authors.forename: J R
authors.initials: JR
authors.lastname: Rodríguez-Mowbray
authors.affiliation: Hospital Clínic, Barcelona, Spain. jmaurel@clinic.ub.es.
authors.forename: J
authors.initials: J
authors.lastname: Maurel
mesh_terms: D001661:Biliary Tract Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019468:Disease Management; D055088:Early Detection of Cancer; D006801:Humans; D008495:Medical Oncology; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic / Q000592:standards*; D011379:Prognosis; D011788:Quality of Life; D012955:Societies, Medical
keywords: Biliary tract cancer; Cholangiocarcinoma; Gall bladder cancer